Appointment as Joint Broker: Summit Therapeutics plc
Panmure Gordon (UK) Limited is pleased to announce the appointment as Joint Broker to Summit Therapeutics plc with immediate effect.
Summit Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications, for which there are no existing or only inadequate therapies. Summit is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy and the infectious disease C. difficile infection.
Further information is available at http://www.summitplc.com/ and Summit can be followed on Twitter (@summitplc).